<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03541083</url>
  </required_header>
  <id_info>
    <org_study_id>HO146</org_study_id>
    <secondary_id>2017-000766-30</secondary_id>
    <nct_id>NCT03541083</nct_id>
  </id_info>
  <brief_title>Blinatumomab Added to Prephase and Consolidation Therapy in Precursor B-acute Lymphoblastic Leukemia in Adults.</brief_title>
  <acronym>HOVON146ALL</acronym>
  <official_title>Blinatumomab Added to Prephase and Consolidation Therapy in Precursor B-acute Lymphoblastic Leukemia in Adults. A Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stichting Hemato-Oncologie voor Volwassenen Nederland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stichting Hemato-Oncologie voor Volwassenen Nederland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Blinatumomab is a new active bispecific monoclonal antibody for treatment of lymphoid
      malignancies, including ALL (acute Lymphoblastic Leukemia ) whose activity for remission
      induction needs to be explored in combination with standardized treatment in order to improve
      outcome of this disease which is still lethal in most adult patients. Ultimate proof of
      efficacy resides in an increase of reaching MRD ( minimal residual disease) negativity,
      prolongation of that response, and long-term survival. Since hematological response rate in
      adult ALL is high already and defining long-term survival in a large clinical trial takes
      many years, this trial aims to improve the strength of the MRD response as defined by
      achieving complete MRD negative response (ie, &lt; 10^-4) after the first consolidation phase
      including blinatumomab. This MRD response will be assessed by Real-Time Quantitative
      Polymerase Chain Reaction (RQ-PCR) analysis of patient-specific Ig/TCR (T-cell receptor )
      gene rearrangements. When MRD data are missing, MRD positivity will be assumed. Although
      younger (up to 40 years of age) patients are treated more intensively than older patients
      (older than 40 years of age), the investigational questions concerning blinatumomab can be
      examined in both subgroups as both younger and older patients receive the same type of
      chemotherapy courses with dose adjustments for chemotherapeutic agents only for patients
      above 60 years of age.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial aims to improve the strength of the MRD ( minimal residual disease) response as
      defined by achieving complete MRD negative response (ie, &lt; 10^-4) after the first
      consolidation phase including blinatumomab.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 4, 2018</start_date>
  <completion_date type="Anticipated">December 15, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of patients that achieve MRD ( minimal residual disease) negative response, measured by Polymerase Chain Reaction (PCR), after the first blinatumomab consolidation course. MRD negative response is defined as MRD &lt;10-4</measure>
    <time_frame>1 year after closure of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete and molecular response rate following induction and after blinatumomab consolidation ll by the addition of i.v. blinatumomab to standard prophase, consolidation and intensification therapy</measure>
    <time_frame>1 year after closure of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival (EFS)</measure>
    <time_frame>1 year after closure of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free survival (RFS)</measure>
    <time_frame>1 year after closure of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>1 year after closure of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events; assessing the safety and toxicity of adding blinatumomab to standard prophase and consolidation therapy (two times) in adult ALL</measure>
    <time_frame>1 year after closure of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RFS and OS from start allogeneic transplantation and from start maintenance RFS</measure>
    <time_frame>1 year after closure of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of molecular and flowcytometric MRD measurements at the same timepoints</measure>
    <time_frame>1 year after closure of study</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>ALL, Adult</condition>
  <arm_group>
    <arm_group_label>Blinatumomab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After a 5-day steroid prephase patients will receive two weeks continuous infusion of blinatumomab. Then the first remission-induction course will be given after one week interruption. Subsequent therapy with 4 cycles of chemotherapy and two 4-week courses of blinatumomab will follow, and subsequently depending on risk group, eligibility and a suitable donor either allogeneic stem cell transplantation or 2 year maintenance treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Blinatumomab</intervention_name>
    <description>prephase and consolidation (I and II)</description>
    <arm_group_label>Blinatumomab</arm_group_label>
    <other_name>Blincyto</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary CD19 (cluster of differentiation antigen 19) positive precursor B-ALL
             (excluding mature B-cell ALL and B-lymphoblastic lymphoma, but including Philadelphia
             positive/BCR-ABL (Abelson murine leukemia viral oncogene homolog 1) positive ALL) and
             CD19 positive mixed phenotype acute lymphoblastic leukemia (MPAL);

          -  Patients aged 18 to 70 years inclusive;

          -  WHO ( World Health Organization) performance status 0-2;

          -  Negative pregnancy test at inclusion, if applicable;

          -  Written informed consent;

          -  Patient is capable of giving informed consent.

        Exclusion Criteria:

          -  Mature B-cell leukemia/lymphoma, B-lymphoblastic lymphoma, isolated extramedullary
             disease;

          -  CML (Chronic myeloid leukemia) in blast crisis;

          -  Acute undifferentiated leukemia;

          -  Previous treatment with chemotherapy for precursor B-ALL (maximum 5 days of steroid
             treatment is allowed)

          -  Persistent liver enzyme disorders (ASAT/ALAT) &gt;5xULN (Upper Limit of Normal) despite
             steroid pre-treatment (see also 8.1.3.)

          -  Severe cardiovascular disease (arrhythmias requiring chronic treatment, congestive
             heart failure or symptomatic ischemic heart disease);

          -  Severe pulmonary dysfunction (CTCAE grade III-IV, see appendix D);

          -  Severe neurological or psychiatric disease;

          -  Active, uncontrolled infection;

          -  Clinically overt central nervous system disease;

          -  History of active malignancy during the past 5 years with the exception of basal cell
             carcinoma of the skin or stage 0 cervical carcinoma;

          -  Patient known to be HIV-positive;

          -  Pregnant or breast-feeding female patients;

          -  Unwilling or not capable to use effective means of birth control (all men, all
             premenopausal women under the age of 50 need contraception for two years after the
             last period, and women older than 50 years for at least one year);

          -  Current participation in another clinical trial;

          -  Any psychological, familial, sociological and geographical condition potentially
             hampering compliance with the study protocol and follow-up schedule.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>A.W. Rijneveld, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus MC, Rotterdam</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>A.W. Rijneveld, Dr.</last_name>
    <phone>010-7033123</phone>
    <email>a.rijneveld@erasmusmc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>J.A. Maertens, Prof.</last_name>
    <phone>+32 (0)16 346880</phone>
    <email>johan.maertens@uzleuven.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UZA</name>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>A. Gadisseur, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ZNA Antwerpen</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>D. Breems, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ st Jan</name>
      <address>
        <city>Brugge</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>D. Sellesslag, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>J. Maertens, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Delta</name>
      <address>
        <city>Roeselare</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>D. Deeren, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Meander MC</name>
      <address>
        <city>Amersfoort</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>S.K Klein, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Amsterdam Medical Centre (AMC)</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>B. Biemond, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>VU medical Centre</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>E. Meijer, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hagaziekenhuis, locatie Leyweg</name>
      <address>
        <city>Den Haag</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>M.R. Schipperus, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medisch Spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>M.C.J.C. Legdeur, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UMCG</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>M. Bellido, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>LUMC</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>C.J.M. Halkes, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Antonius Ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>O. De Weerdt, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A.W. Rijneveld, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UMCU</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>E.J Petersen, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Isala</name>
      <address>
        <city>Zwolle</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>M. Van Marwijk Kooy, Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.hovon.nl</url>
    <description>The foundation of Hemato-Oncologie voor Volwassenen Nederland (HOVON - the Haemato Oncology Foundation for Adults in the Netherlands).</description>
  </link>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>March 20, 2018</study_first_submitted>
  <study_first_submitted_qc>May 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2018</study_first_posted>
  <last_update_submitted>July 20, 2018</last_update_submitted>
  <last_update_submitted_qc>July 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Blinatumomab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

